Suchergebnisse

BACKGROUND: Major cardiac events including myocardial infarction (MI) are associated with viral infections. However, how specific infections contribute to the cardiovascular insults has remained largely unclear. METHODS: We employed next generation phage display mimotope-variation analysis (MVA) to explore the link between antibody-based immune response and severe cardiovascular conditions. Here, we used a case-control design, including the first-stage discovery cohort (n = 100), along with cohorts for second-stage discovery (n = 329) and validation (n = 466). FINDINGS: We observed strong antibody response to the peptide antigens with Gly-Ile-X-Asp (G-I-X-D) core structure in healthy individuals but not in patients with MI. Analysis of the origin of this epitope linked it with the N-terminus of the VP1 protein of poliovirus 3 (PV3), but also other species of picornaviruses. Consistently, we found low levels of antibody response to the G-I-X-D epitope in individuals with severe cardiac disease complications. INTERPRETATION: Our findings imply that antibody response to the G-I-X-D epitope is associated with polio vaccinations and that high antibody levels to this epitope could discriminate healthy individuals from prospective MI patients as a blood-derived biomarker. Together, these findings highlight the importance of epitope-specific antibody response and suggest that protective immunity against the polio- and non-polio enteroviral infections support improved cardiovascular health. FUNDING: Estonian Ministry of Education (5.1-4/20/170), Estonian Research Council (PRG573, PRG805), H2020-MSCA-RISE-2016 (EU734791), H2020 PANBioRA (EU760921), European Union through the European Regional Development Fund (Project no. 2014-2020.4.01.15-0012), Helsinki University Hospital grants, Mary and Georg C. Ehrnrooth Foundation, Finnish Eye Foundation, Finska Läkaresällskapet, The Finnish Society of Sciences and Letters, Magnus Ehrnrooth Foundation and Sigrid Jusélius Foundation.

In order to detect serum antibodies against clinically important Old and New World hantaviruses simultaneously, multiparametric indirect immunofluorescence assays (IFAs) based on biochip mosaics were developed. Each of the mosaic substrates consisted of cells infected with one of the virus types Hantaan (HTNV), Puumala (PUUV), Seoul (SEOV), Saaremaa (SAAV), Dobrava (DOBV), Sin Nombre (SNV) or Andes (ANDV). For assay evaluation, serum IgG and IgM antibodies were analyzed using 184 laboratory-confirmed hantavirus-positive sera collected at six diagnostic centers from patients actively or previously infected with the following hantavirus serotypes: PUUV (Finland, n = 97); SEOV (China, n = 5); DOBV (Romania, n = 7); SNV (Canada, n = 23); ANDV (Argentina and Chile, n = 52). The control panel comprised 89 sera from healthy blood donors. According to the reference tests, all 184 patient samples were seropositive for hantavirus-specific IgG (n = 177; 96%) and/or IgM (n = 131; 72%), while all control samples were tested negative. In the multiparametric IFA applied in this study, 183 (99%) of the patient sera were IgG and 131 (71%) IgM positive (accordance with the reference tests: IgG, 96%; IgM, 93%). Overall IFA sensitivity for combined IgG and IgM analysis amounted to 100% for all serotypes, except for SNV (96%). Of the 89 control sera, 2 (2%) showed IgG reactivity against the HTNV substrate, but not against any other hantavirus. Due to the high cross-reactivity of hantaviral nucleocapsid proteins, endpoint titrations were conducted, allowing serotype determination in .90% of PUUV- and ANDV-infected patients. Thus, multiparametric IFA enables highly sensitive and specific serological diagnosis of hantavirus infections and can be used to differentiate PUUV and ANDV infection from infections with Murinae-borne hantaviruses (e.g. DOBV and SEOV). ; Fil: Lederer, Sabine. EUROIMMUN Medizinische Labordiagnostika; Alemania ; Fil: Lattwein, Erik. EUROIMMUN Medizinische Labordiagnostika; Alemania ; Fil: Hanke, Merle. EUROIMMUN Medizinische Labordiagnostika; Alemania ; Fil: Sonnenberg, Karen. EUROIMMUN Medizinische Labordiagnostika; Alemania ; Fil: Stoecker, Winfried. EUROIMMUN Medizinische Labordiagnostika; Alemania ; Fil: Lundkvist, Åke. Karolinska Huddinge Hospital. Karolinska Institutet; Suecia ; Fil: Vaheri, Antti. University of Helsinki; Finlandia ; Fil: Vapalahti, Olli. University of Helsinki; Finlandia ; Fil: Chan, Paul K. S. Chinese University of Hong Kong; República de China ; Fil: Feldmann, Heinz. Canadian Science Centre for Human and Animal Health. Public Health Agency of Canada; Canadá ; Fil: Dick, Daryl. Canadian Science Centre for Human and Animal Health. Public Health Agency of Canada; Canadá ; Fil: Schmidt Chanasit, Jonas. Bernhard Nocht Institute for Tropical Medicine; Alemania ; Fil: Padula, Paula Julieta. Dirección Nacional de Instituto de Investigación. Administración Nacional de Laboratorio e Instituto de Salud; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina ; Fil: Vial, Pablo A. Universidad del Desarrollo; Chile ; Fil: Panculescu Gatej, Raluca. CANTACUZINO National Institute for Research and Development in Microbiology and Immunology; Rumania ; Fil: Ceianu, Cornelia. CANTACUZINO National Institute for Research and Development in Microbiology and Immunology; Rumania ; Fil: Heyman, Paul. Queen Astrid Military Hospital; Bélgica ; Fil: Avšič Županc, Tatjana. Institute of Microbiology and Immunology; Eslovenia ; Fil: Niedrig, Matthias. Robert Koch Institute; Alemania